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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S142infection within 2years of their surgery, but did not differ in terms of
risk for DVT/PE, early revision, infection, peri-prosthetic fracture or
death following TKA. To our knowledge, this is the ﬁrst study that has
utilized a validated algorithm to identify TKA recipients with RA,
thereby increasing the validity of our ﬁndings, and aiding patient-
physician decision-making around joint replacement in patients with
RA. Further research is required to elucidate potential explanations for
the higher rates of infection in RA versus OA, including the use of bio-
logic agents.
261
MORE PROMINENT INFLAMMATORY FEATURES IN KNEE
OSTEOARTHRITIS IN THE PRESENCE OF CONCOMITANT HAND
OSTEOARTHRITIS
C. Orellana, N. Navarro, J. Calvet, M. García-Manrique, J. Gratacós,
M. Larrosa. CSiU Parc Taulí. Hosp. de Sabadell, Sabadell, Spain
Background: In recent years it has been recognized the existence of
a link between hand osteoarthritis and systemic inﬂammation. On the
other hand, a signiﬁcant proportion of patients with knee osteoarthritis
show local clinically evident inﬂammatory features such as synovial
effusion and synovial hypertrophy.
Purpose: To evaluate if patients with knee osteoarthritis show more
inﬂammatory signs as measured by ultrasound when hand osteoar-
thritis is concomitantly present.
Methods: Patients aged 50 years or more with symptomatic osteoar-
thritis of the knee and joint effusion, Kellgren-Lawrence II-III. Demo-
graphics, BMI, disease duration, pain assessed by VAS (0-100 mm) and
algofuncional Lequesne index were assessed. Knee ultrasound was
performed evaluating and measuring the presence of effusion and
synovial hypertrophy (deﬁned as > 4 mm synovial thickening) at the
suprapatellar midline.
Results: In a cross-sectional study we analyzed 50 patients, F/M 39/11,
age 61.8 10.1 years, disease duration 50.8 6.3 months, BMI 28 1.4
kg/cm2. Ten patients (20%) had concomitant hand osteoarthritis. There
were no signiﬁcant differences in age, disease duration, BMI or radio-
logical grade between patients with knee and hand osteoarthritis
compared with those with only knee osteoarthritis. On ultrasound
examination patients with concomitant hand osteoarthritis showed
a clear trend to have a more prominent joint effusion (7.39  3 vs. 6.7
2.8 mm) and synovial hypertrophy (3.6  2.6 vs. 2.7 1.8 mm),
although not statistically differences were found. Patients with
concomitant hand osteoarthritis also had a non-signiﬁcant trend to
experience greater knee pain (VAS 70.3 12.5 vs. 61 18.5 mm) and
Lesquesne index scores (11.4 3.3 vs. 9.8 2.9).
Conclusions: Although results were not statistically signiﬁcant prob-
ably in relation to small size sample, in this study the presence of hand
osteoarthritis appeared to be associated with greater inﬂammatory
features in patients with symptomatic knee osteoarthritis.
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NETWORKING TO CAPTURE PATIENT-REPORTED OUTCOMES
DURING ROUTINE ORTHOPAEDIC CARE ACROSS TWO DISTINCT
INSTITUTIONS
R. Karia y, J. Slover y, C. Hauer z, Z. Gelber y, P. Band y, J. Graham z. yNew
York Univ. Sch. of Med., NY, USA; zGeisinger Med. Systems, Danville, PA,
USA
Purpose: Osteoarthritis of the knee is a chronic disease associated with
pain and reduced quality of life, and the ability to reliably measure
patient-reported symptoms is important for clinical decision-making
and as a tool for future clinical research. A large number of validated
questionnaires for this purpose have been developed, but they are
typically restricted to use in research studies because of the logistical
barriers to integrating paper-based questionnaires into routine clinic
workﬂow. Electronic and web-based tools can eliminate much of the
labor-intensive aspects of questionnaire administration and enable
real-time evaluation of responses by physicians and integration of data
frommultiple sites for research purposes. The purpose of this study was
to evaluate the implementation of a single integrated electronic
outcome measurement system into routine orthopaedic practice at two
distinct institutions, one urban and one rural.
Methods: A web-based version of a preference-based quality-of-life
(EQ-5D) and a disease-speciﬁc (KOOS Pain) questionnaire was admin-
istered to all knee patients at two centers over a 9-month period usingtouchscreen devices. Data was analyzed for each institution and the
combined institutions using descriptive statistics.
Results: The methodology for data collection and IT support was found
to require customization to the established workﬂow at each institution
in order to minimize practice disruption. A total of 666 patients were
enrolled between both institutions. Patient compliance was 93% and
95%, respectively. Average questionnaire completion times were 3-5
minutes. Feedback elicited from patients was positive and indicated
patient willingness to participate in the process, and their satisfaction
with the process. Feedback from surgeons indicated that the process
provided helpful clinical information, and was not disruptive to their
clinical workﬂow. Mean EQ-5D and KOOS scores for patients pre- and
post-surgery were consistent with prior literature reports, supporting
the applicability of the outcome data collected for use in routine clinical
practice.
Conclusions: These data demonstrate that validated outcome scores
can be routinely collected as part of standard care, and can contribute to
both patient care and clinical research. Pragmatic clinical data collected
during routine care will become increasingly important for quality
control and comparative effectiveness research in orthopaedic medi-
cine.263
PREDICTIVE FACTORS FOR ONSET OF OA ACCORDING TO THE ACR
CRITERIA IN THE CHECK STUDY
J. Damen y, R. Van Rijn y, P. Emans z, S. Bierma-Zeinstra y. y Erasmus MC,
Rotterdam, The Netherlands; zMaastricht UMC, Maastricht, The
Netherlands
Purpose: In this study we aim to establish how many participants with
pain in hip and/or knee due to early osteoarthritis (OA) develop hip and
knee OA after two years of follow-up according to the ACR (American
college of rheumatism) guidelines. Furthermore we will try to identify
predictive factors for developing such OA.
Methods: We used the prospective CHECK study that included 1002
participants with pain of the knee and/or hip to be due to early
symptomatic OA. Primary outcome of the present study was onset of
hip and/or knee OA according to ACR criteria after 2 years of follow-up.
Predictive factors for onset of evident hip and or knee OA are assessed
with multivariate logistic regression.
Results: Of the participants with hip complaints at baseline 27.6%
(n¼162) and 50.0% (n¼295) were classiﬁed as having hip OA at baseline
according to the ACR clinical criteria and the combined clinical and
radiographic criteria for hip OA respectively. Of the participants with
knee complaints 81.3% (n¼674) and 73.1% (n¼606) participants were
classiﬁed as having knee OA at baseline according to the ACR clinical
criteria and the combined clinical and radiographic criteria for knee OA
respectively.
In the participants with hip complaints who were not classiﬁed as
having hip OA at baseline according to the clinical classiﬁcation criteria
(n¼426), we could analyse all factors in 400 participants after 2 years of
follow up of which 13.6% (n¼58) developed hip OA. For the combined
clinical and radiographic classiﬁcation criteria 295 participants were
classiﬁed with hip OA at baseline, after two years we could asses 264
participants of which 7.4% (n¼21) developed hip OA.
In the group of participants with knee complaints who were not clas-
siﬁed as having knee OA at baseline according to the clinical classiﬁ-
cation criteria (n¼155) we could assess 155 participants after 2 years of
follow up. Of these 33.5% (n¼52) developed knee OA. In the group of
participants with knee complaints 218 participants were classiﬁed as
non-knee OA according to the combined clinical and radiographic
classiﬁcation criteria. We analysed 210 participants after 2 years of
follow up of which 25.2% (n¼55) developed knee OA.
For the ACR clinical classiﬁcation criteria medication use (OR 2.74; 95%
CI 1.42- 5.31) and morning stiffness (OR 2.74; (1.02-3.47) were predic-
tive factors. And for the ACR combined clinical and radiographic clas-
siﬁcation criteria predictive factors were stiffness of the hip (OR 3.16;
95% CI 1.12-8.91), and the presence of Heberden's nodes (OR 10.65; 95%
CI 2.86-39.61). Bilateral complaints were negatively associated with the
occurrence of hip OA (OR 0.18; 95% CI 0.04-0.82).
For the ACR clinical classiﬁcation criteria we could not identify
predictive factors.
For the ACR combined clinical and radiographic classiﬁcation criteriawe
could identify Heberden's nodes as a predictive factor (OR 2.77; 95% CI
1.40-5.49).
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S143Conclusions: In 2 years of follow up substantial numbers of participants
with complaints due to early OA could be diagnosed according to
clinical or radiographic ACR criteria with either hip or knee OA after two
years of follow up. Speciﬁc factors associated with this progression
found in the hip group: morning stiffness of the hip, pain medication
use, and Heberden's nodes. In the knee group Heberden's nodes were
associated with the diagnosis of knee OA.
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STRONTIUM RANELATE INCREASES THE NUMBER OF PATIENTS WITH
IMPROVEMENT IN OSTEOARTHRITIS SYMPTOMS COMPARED TO
PLACEBO IN THE SEKOIA STUDY
O. Bruyere y, P. Richette z, N. Bellamy x, J. Brown k, R. Chapurlat {,
X.-J. Chevalier #, E. Czerwinski yy, J.-P. Devogelaer zz, L. March xx,Placebo (N ¼ 472) n (%) SrRan 2 g (N ¼ 454) n (%) Difference relative to placebo [95% CI] p-value
WOMAC
Responders 20% 297 (64.0) 317 (72.0) 8.0 [2.0 ; 14.1] 0.010
Responders 50% 208 (44.8) 223 (50.7) 5.9 [-0.7 ; 12.4] 0.078
WOMAC Pain subscore
Patients above MPCI threshold (9.7mm) 255 (55) 289 (65.5) 10.6 [4.2 ; 16.9] 0.001
WOMAC Stiffness subscore
Patients above MPCI threshold (10mm) 247 (52.8) 270 (60.1) 7.4 [0.9 ; 13.8] 0.025
WOMAC Physical function subscore
Patients above MPCI threshold (9.3mm) 229 (49.1) 257 (57.9) 8.7 [2.3 ; 15.2] 0.008
Patients above MCII threshold (-9.1mm) 231 (49.6) 257 (57.9) 8.3 [1.9 ; 14.8] 0.012
Knee pain by VAS
Responders 20% 325 (69.7) 336 (76.0) 6.3 [0.5 ; 12.0] 0.034
Responders 50% 249 (53.4) 263 (59.5) 6.1 [-0.4 ; 12.5] 0.065
Patients above MCII threshold (-19.9mm) 277 (59.4) 302 (67.7) 8.3 [2.1; 14.5] 0.010
OMERACT-OARSI-like responders 221 (47.0) 244 (54.0) 7.0 [0.5 ; 13.4] 0.035
MPCI responders were statistically signiﬁcantly greater fromM18 (pain and functionWOMAC sub-scores, p¼ 0.003 and p¼ 0.013, respectively), and after 2 years for stiffness
sub-score (p¼ 0.008), being close to statistical signiﬁcance (p¼ 0.051) for physical function sub-score. When considering withdrawn patients as non-responders, results were
similar.K. Pavelka kk, L. Punzi {{, C. Cooper ##, J.-Y. Reginster yyy. yDept. of Publ.
Hlth., Epidemiology and Hlth.Economics, Liège, Belgium; zUniversité
Paris 7 UFR médicale Assistance Publique-Hôpitaux de Paris Hosp.
Lariboisière Fédération de Rhumatologie, Paris, France; x The Univ. of
Queensland, Brisbane, Australia; k Ctr. de recherche du CHU de Québec -
Dept. of Medecine, Faculty of Med., Laval Univ. and Rheumatology Div.
CHU de Québec, Québec, QC, Canada; { INSERM UMR 1033. Université de
Lyon Hosp. E. Herriot, Lyon, France; #Hosp. H. Mondor Dept. of
Rheumatology Univ. Paris XII UPEC, Créteil, France; yyKrakowskie
Centrum Medyczneul Kopernika 32, Krakow, Poland; zzUniversité
Catholique de Louvain Saint Luc Univ. Hosp., Brussels, Belgium; xxUniv.
of Sydney Inst. of Bone and Joint Res. and Rheumatology Dept. Royal
North Shore Hosp. St Leonards NSW 2065, Sydney, Australia; kk Inst. of
Rheumatology Na Slupi 4 128 50, Prague, Czech Republic;
{{Rheumatology Unit Dept. of Med. DIMED, Padova, Italy; ##MRC
Lifecourse Epidemiology Unit Univ. of Southampton, Southampton,
United Kingdom; yyyDept. of Publ. Hlth.Epidemiology and Hlth.Economics
Univ. of Liège, Liège, Belgium
Purpose: In SEKOIA study, strontium ranelate 2g/day (SrRan) has
shown structure-modifying activity associated with statistically signif-
icant symptomatic improvement compared to placebo in patients with
knee osteoarthritis (OA). The purpose of this analysis was to determine
the proportion of patients considered as symptomatic responders as per
WOMAC pain sub-score or pain VAS improvement and OMERACT-
OARSI-like responders, as well as the number of patients reaching MPCI
(Minimal Perceptible Clinical Improvement) and MCII (Minimal Clinical
Important Improvement).
Methods: SEKOIA study was a double-blind, placebo-controlled,
randomized, international 3-year study aiming to demonstrate the
effects of strontium ranelate on the radiographic progression of knee
osteoarthritis. It included men and women over 50 years old, with
symptomatic primary knee OA (at least 40 on a 100 mm visual analog
scale (VAS) on most days of the previous month, Kellgren and Lawrence
[KL] grade 2 or 3, and joint space width [JSW] 2.5-5 mm). Symptomswere assessed every 6 months over 3 years using the WOMAC ques-
tionnaire and a 100 mm VAS. Proportions of patients with an
improvement of at least 20% or 50% from baseline of their WOMAC pain
sub-score or pain VAS, proportion of OMERACT-OARSI-like responders
(calculated using improvement in pain and function but not patient's
global assessment as it was not assessed in this study) and percentages
of patients reaching MPCI or MCII published values, were compared
between groups using a chi2 test.
Results: The ITT population included 1371 (82%) patients presenting at
baseline, mean  SD, an age of 637 years, BMI of 305 kg/m2, VAS of
5422 mm, and WOMAC of 13262 mm. 61% were KL grade II and 69%
were female. Over 3 years, a greater percentage of patients treated with
SrRan 2g were considered as symptomatic responders compared to
placebo:Conclusions: Treatment with SrRan is associated with a greater
number of patients with relevant improvement in symptoms. This can
be evidenced from M18 considering MPCI responders.265
STRONTIUM RANELATE PREVENTS RADIOLOGICAL PROGRESSION IN
PATIENTS WITH PRIMARY KNEE OSTEOARTHRITIS: A RESPONDERS
ANALYSIS
C. Cooper y, F. Berenbaum z, P. Nash x, O. Zamani k, M. Cohen-Solal {,
G. Bianchi #, B. Jaime yy, F. Navarro zz, J.-Y. Reginster xx. yMRC Lifecourse
Epidemiology Unit Univ. of Southampton, Southampton, United
Kingdom; zUniv. Pierre & Marie CURIE AP-HP Saint Antoine Hosp., Paris,
France; xAssoc. Prof. Dept of Med. Univ. of Queensland, Queensland,
Australia; k Clinical Res. Ctr., Rheuma Zentrum Favoriten, Wien, Austria;
{ INSERM U606 - Univ. Paris- Diderot - Hosp. Lariboisière, Paris, France;
#Div. of Rheumatology ASL 3 Genovese, Genoa, Italy; yyCEDOC
Faculdade Ciências Medicas UNL Rheumatology Dept. CHLO Hosp. Egas
Moniz, Lisboa, Portugal; zzUniversity Hosp. Virgen Macarena Chief.
Service of Rheumatology, Sevilla, Spain; xxUniv. of Liège Dept. of Publ.
Hlth.Epidemiology and Hlth.Economics, Liège, Belgium
Purpose: Strontium ranelate (SrRan) has demonstrated a structure-
modifying activity associated with symptoms improvement in patients
with knee osteoarthritis (OA) in a large, randomised, placebo-
controlled, double-blind phase-III 3-year study (SEKOIA study). The aim
of this analysis was to describe the proportion of patients in whom
radiological OA progression was prevented on each treatment group,
when considering different cut-offs of JSN.
Methods: The SEKOIA study included patients with symptomatic
primary knee OA (Kellgren and Lawrence [KL] grade 2 or 3, joint space
width [JSW] 2.5-5 mm) randomly allocated to SrRan 1 or 2 g/day, or
placebo. Primary endpoint was radiographic change in JSW of the
medial tibiofemoral compartment from baseline to LOCF. JSW was
measured yearly using a validated computer-assisted centralised
